<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="227540">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00119600</url>
  </required_header>
  <id_info>
    <org_study_id>20030205</org_study_id>
    <nct_id>NCT00119600</nct_id>
  </id_info>
  <brief_title>A Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy</brief_title>
  <official_title>A Randomised, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Finding Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of
      AMG 114 administered subcutaneously for the treatment of chemotherapy induced anemia in
      subjects receiving multicycle chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hemoglobin concentration</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Time Cmax is observed (Tmax)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in FACT-fatigue sub-scores</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <condition>Anemia</condition>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 114</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Part A: - Non-myeloid malignancy receiving multicycle chemotherapy -
        Receiving non-platinum containing chemotherapy - At least 6 additional weeks of cyclic
        cytotoxic chemotherapy planned Part B and Part C: - Non-myeloid malignancy receiving
        multicycle chemotherapy - At least 12 additional weeks of cyclic cytotoxic chemotherapy
        planned All Parts: - Chemotherapy induced anemia - Greater than 6 month life expectancy -
        ECOG 0-2 - Adequate renal and liver function Exclusion Criteria: - Chronic myeloid
        leukemia, AML, ALL, Burkitt's lymphoma or lymphoblastic lymphoma - History of seizure
        disorder - Primary hematologic disorder which could cause anemia, other than a non-myeloid
        malignancy - Unstable angina, congestive heart failure or uncontrolled cardiac arrhythmia
        - Uncontrolled hypertension - History of pure red cell aplasia - Clinically significant
        inflammatory disease or active infection - Iron deficiency - ANC less than 0.8 x 10^9
        cells/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>May 2009</verification_date>
  <lastchanged_date>May 7, 2009</lastchanged_date>
  <firstreceived_date>July 6, 2005</firstreceived_date>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Non-myeloid malignancy</keyword>
  <keyword>Clinical Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
